Ernexa Therapeutics Inc.
ERNA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000748592
No open-market purchases or sales by Ernexa Therapeutics Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $236.2K in total; no superinvestor holds it.
Other share classesERNAW
13F holders, Q3 2025
Institutional positions in Ernexa Therapeutics Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- +2 vs. Q2 2025
- Shares held
- 516.9K
- +467.1K (+937.8%) vs. Q2 2025
- Total value
- $566.0K
- +$474.4K (+517.6%) vs. Q2 2025
- New holders
- 3
- 3 more added
- Sold out
- 1
- 1 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ERNA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 10 | $236.2K |
| Q1 2026 | 20 | $711.4K |
| Q4 2025 | 14 | $627.1K |
| Q3 2025 | 14 | $566.0K |
| Q2 2025 | 12 | $91.7K |
| Q1 2025 | 27 | $264.2K |
| Q4 2024 | 24 | $292.4K |
| Q3 2024 | 20 | $746.9K |
| Q2 2024 | 20 | $712.4K |
| Q1 2024 | 23 | $981.1K |
| Q4 2023 | 20 | $636.9K |
| Q3 2023 | 22 | $728.4K |
| Q2 2023 | 20 | $750.2K |
| Q1 2023 | 21 | $1.14M |
| Q4 2022 | 20 | $1.19M |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Ernexa Therapeutics Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| CI Private Wealth, LLC | 438,092 | $479.7K | 0.00% | +420,569+2,400.1% | Added |
| Susquehanna International Group, LLP | 30,854 | $33.8K | 0.00% | +30,854 | New |
| Geode Capital Management, LLC | 20,453 | $22.4K | 0.00% | +378+1.9% | Added |
| Vanguard Group Inc | 11,147 | $12.2K | 0.00% | +11,147 | New |
| Sippican Capital Advisors | 10,000 | $10.9K | 0.01% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 5,182 | $5.67K | 0.00% | +5,182 | New |
| BlackRock, Inc. | 820 | $898 | 0.00% | 00.0% | Unchanged |
| Assetmark, Inc | 133 | $146 | 0.00% | 00.0% | Unchanged |
| EverSource Wealth Advisors, LLC | 116 | $127 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 77 | $84 | 0.00% | −477−86.1% | Reduced |
| Bank of America Corp | 33 | $36 | 0.00% | +12+57.1% | Added |
| BNP Paribas Arbitrage, SA | 10 | $11 | 0.00% | 00.0% | Unchanged |
| Montag A & Associates Inc | 8 | $9 | 0.00% | 00.0% | Unchanged |
| Activest Wealth Management | 3 | $3 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 0 | $0 | 0.00% | −548−100.0% | Sold out |